The Diversified Stock Income Plan (DSIP) List has an extensive track record, dating back to its inception of November 30, 1993 our new report takes a look back at the List's performance, volatility, and dividend growth over the years
2 Broadening Boehringers Obesity Strategy The Phase II program follows encouraging Phase I safety and tolerability data and complements Boehringer Ingelheims expanding obesity portfolio, including survodutide, the companys dual #glucagon/ #GLP-1 agonist currently advancing through Phase III development, alongside additional next-generation injectable and oral metabolic therapies
An obesity medicine specialist breaks down the reactions you can encounter with GLP-1 drugs
As weve seen from the wildly popular yet potentially dangerous GLP-1 drugs, they have a huge number of drawbacks and potential complications
The MedSpa Society has created organic social graphics proven and tested to resonate with your audience
Note: some secondary sources cite the 2018 Neelakantan Biochem Pharmacol paper under differing PMIDs (29155147 vs 29355482)
